EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Novel Claudin18.2-Targeted Therapies in Gastrointestinal Tumors

Wei Ye, Mengting Xu, Yijie Gu, Wen-Bin Ou iD

ACS Omega · 16.09.2025 · 10 (36) · 40793-40804

DOI: 10.1021/acsomega.5c06506 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ACS Omega, online erschienen am 02.09.2025. Verfasst von Wei Ye und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biopharmaceutics, Zhejiang Provincial Key Laboratory of Silkworm Bioreactor and Biomedicine, Zhejiang Sci-Tech University, Hangzhou 310…. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Zhejiang Sci-Tech University, National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastrointestinal (GI) tumors are a type of malignant tumor characterized by their increasing incidence and lethality. Thus, there is an urgent need to explore more peculiar treatment targets. Recently, the adhesion protein claudin18.2 (CLDN18.2) has emerged as a promising target for expanding the scope of targeted therapy for GI tumors because it facilitates the proliferation and evasion of tumor cells through mediation of PI3K-AKT and RAF-MAPK signaling pathways and tumor microenvironment. Therapies targeting CLDN18.2 have advanced considerably, prompting research into new combination regimens and modified CLDN18.2 targeted drug using nanoparticles and CAR-T-modified drugs. There is a compelling rationale to prioritize the investigation of the significance of CLDN18.2 in GI tumors. The unique expression of CLDN18.2 renders it as a promising biomarker for developing precision-guided therapeutic interventions for GI tumors.

Autor:innen und Institutionen

  • Department of Biopharmaceutics, Zhejiang Provincial Key Laboratory of Silkworm Bioreactor and Biomedicine, Zhejiang Sci-Tech University, Hangzhou 310018, China.
  • Zhejiang Provincial Engineering Research Center of New Technologies and Applications for Targeted Therapy of Major Diseases, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China.

ORCID-Profile: Wen-Bin Ou

Förderung

  • Zhejiang Sci-Tech University
  • National Natural Science Foundation of China
  • Natural Science Foundation of Zhejiang Province

Zitieren

APA

Ye, W., Xu, M., Gu, Y., & Ou, W. B. (2025). Novel Claudin18.2-Targeted Therapies in Gastrointestinal Tumors. ACS Omega, 10(36), 40793-40804. https://doi.org/10.1021/acsomega.5c06506

Vancouver

Ye W, Xu M, Gu Y, Ou WB. Novel Claudin18.2-Targeted Therapies in Gastrointestinal Tumors. ACS Omega. 2025;10(36):40793-40804. doi:10.1021/acsomega.5c06506

BibTeX
@article{Ye2025,
  author = {Ye, Wei and Xu, Mengting and Gu, Yijie and Ou, Wen-Bin},
  title = {Novel Claudin18.2-Targeted Therapies in Gastrointestinal Tumors},
  journal = {ACS Omega},
  year = {2025},
  volume = {10},
  number = {36},
  pages = {40793--40804},
  doi = {10.1021/acsomega.5c06506}
}
Kostenlos starten →